Psilocybin History Timeline

Ancient Mesoamerican Use: Teonanácatl and the Mushroom Cults

The history of psilocybin mushrooms as a tool for spiritual and healing practice stretches back at least 3,000 years, and possibly much longer. Archaeological evidence — including "mushroom stones" carved in humanoid-fungal forms found throughout Guatemala and southern Mexico — suggests ceremonial mushroom use among Olmec, Mixtec, and Mazatec cultures well before the Common Era. By the time Spanish conquistadors arrived in the 16th century, psilocybin mushrooms were deeply embedded in Aztec religious life under the name teonanácatl, meaning "flesh of the gods" in Nahuatl. The mushrooms were consumed during ritual ceremonies to commune with deities, divine the future, diagnose illness, and receive spiritual guidance.

Spanish missionaries condemned the practice as devil worship and attempted to suppress it, driving mushroom ceremonies underground — where they survived for centuries in isolated communities, particularly among the Mazatec people of Oaxaca. The most celebrated practitioner of the modern era was María Sabina (1894–1985), a Mazatec curandera (healer) who conducted all-night healing ceremonies called veladas in her village of Huautla de Jiménez. Sabina used mushrooms she called niños santos ("holy children") to diagnose illness, speak with spirits, and facilitate psychological healing. She became internationally known — and ultimately controversial within her own community — after the Western world discovered her work in the late 1950s.

1957–1963: Western Discovery and Early Research

In May 1957, investment banker and amateur mycologist R. Gordon Wasson published a landmark article in LIFE magazine titled "Seeking the Magic Mushroom," describing his participation in a velada ceremony with María Sabina the previous year. It was the first major account of psilocybin mushroom use to reach a mainstream Western audience, and the article caused an immediate sensation. Wasson's vivid descriptions of visions, dissolution of self, and profound emotion introduced millions of Americans to the idea that a fungus could produce a transformative spiritual experience. Wasson himself was careful to treat the tradition with respect, though the flood of Western tourists to Huautla de Jiménez that followed caused lasting harm to Sabina and her community.

The scientific world moved swiftly. Swiss chemist Albert Hofmann — already famous for synthesizing LSD in 1938 — successfully isolated the active compounds psilocybin and psilocin from Psilocybe mexicana mushrooms at Sandoz Laboratories in Basel, Switzerland in 1958. This was the first time a psychedelic compound had been identified and produced in pure, reproducible form from a natural mushroom source, opening the door to controlled research. Meanwhile, at Harvard University, psychologist Timothy Leary launched the Harvard Psilocybin Project in 1960, conducting studies on the psychological effects of psilocybin — including the controversial Good Friday Experiment (1962), which investigated whether the compound could reliably induce mystical experiences in a religious context. Leary's increasingly public and evangelical promotion of psychedelics led to his dismissal from Harvard in 1963.

1970–2000: Prohibition and the Research Dark Age

The cultural upheaval of the late 1960s prompted a severe government backlash. The Controlled Substances Act of 1970, signed by President Nixon, classified psilocybin as a Schedule I substance — defined as having "no currently accepted medical use and a high potential for abuse." This effectively ended government-funded psychedelic research in the United States and created legal barriers that persisted for decades. Researchers who wished to study psilocybin faced near-impossible regulatory hurdles, and pharmaceutical companies lost interest entirely. For roughly 25 years, scientific investigation of psilocybin was almost completely halted. A small number of researchers — most notably Alexander Shulgin and Rick Strassman — continued to probe the science in limited ways, and underground therapeutic use persisted quietly, but the mainstream scientific community stayed away.

2000–Present: The Modern Psychedelic Renaissance

The revival began slowly in the late 1990s as a handful of researchers persuaded regulatory agencies to allow carefully controlled studies. The pivotal moment came in 2006, when Roland Griffiths and colleagues at Johns Hopkins University published a landmark study in Psychopharmacology demonstrating that a single high dose of psilocybin could reliably produce mystical-type experiences with long-lasting positive changes in mood, attitude, and behavior in healthy volunteers. The study was rigorous and its findings robust — and it reopened the floodgates of serious scientific inquiry.

Research accelerated dramatically through the 2010s. Robin Carhart-Harris and colleagues at Imperial College London produced groundbreaking neuroimaging studies revealing how psilocybin affects brain connectivity — particularly the default mode network — offering new models for understanding consciousness and depression. Clinical trials for treatment-resistant depression, addiction, and end-of-life anxiety multiplied. In 2018 and 2019, the FDA granted Breakthrough Therapy designations for psilocybin-assisted therapy for treatment-resistant depression and major depressive disorder, significantly accelerating the regulatory pathway toward approval.

On the policy side, Denver, Colorado became the first US city to decriminalize psilocybin mushrooms in May 2019. Oregon passed Measure 109 in November 2020, creating a framework for licensed psilocybin service centers — the first state-level legal therapeutic model in the country. Between 2020 and 2024, dozens of US cities including Oakland, Santa Cruz, Seattle, and Ann Arbor enacted decriminalization measures, and several countries including the Netherlands, Jamaica, and Brazil allow psilocybin mushrooms in various legal contexts. As of 2024, Phase 3 clinical trials are underway and the possibility of FDA-approved psilocybin therapy within this decade is considered realistic by many researchers.

Frequently Asked Questions

How old is the documented use of psilocybin mushrooms?

Archaeological evidence suggests ceremonial mushroom use in Mesoamerica dates back at least 3,000 years. Carved "mushroom stones" found in Guatemala and Mexico, depicting humanoid-fungal figures, are estimated to be 1,000–3,000 years old. Some researchers argue indigenous oral traditions suggest use extending even further, though direct evidence becomes harder to establish before written records.

Who was María Sabina?

María Sabina (1894–1985) was a Mazatec curandera (traditional healer) from Huautla de Jiménez, Oaxaca, Mexico. She was renowned for her all-night mushroom healing ceremonies called veladas, during which she consumed psilocybin mushrooms she called niños santos (holy children) and chanted in Mazatec to commune with spirits and diagnose illness. After R. Gordon Wasson wrote about attending her ceremony in 1957, she became internationally famous — but the tourism that followed brought disruption and hardship to her community.

What did R. Gordon Wasson write about psilocybin mushrooms?

Wasson's 1957 LIFE magazine article "Seeking the Magic Mushroom" described his 1955 participation in a Mazatec velada ceremony with María Sabina. He recounted visions of vivid colors and imagery, feelings of profound awe, and a sense of ego dissolution. It was the first detailed account of a psilocybin ceremony to reach a mass Western audience, and it sparked enormous public and scientific interest in psychedelic mushrooms.

Who is Albert Hofmann and what did he discover?

Albert Hofmann (1906–2008) was a Swiss chemist at Sandoz Laboratories in Basel, Switzerland. He is best known for first synthesizing LSD in 1938. In 1958, he became the first scientist to isolate and identify the active compounds in Psilocybe mexicana mushrooms, naming them psilocybin and psilocin. This allowed researchers to study these compounds in a pure, measurable form for the first time.

What does teonanácatl mean?

Teonanácatl is a Nahuatl word used by the Aztecs to refer to psilocybin-containing mushrooms. It translates roughly as "flesh of the gods" (teo = divine/god, nanácatl = mushroom/flesh). The mushrooms were considered sacred and were consumed during religious and healing ceremonies to access divine knowledge and communicate with deities.

What happened to psilocybin research in 1970?

The US Controlled Substances Act of 1970, signed by President Nixon, classified psilocybin as a Schedule I controlled substance — a category defined as having no accepted medical use and high abuse potential. This made it extremely difficult to obtain the regulatory approvals and funding needed for research, effectively shutting down scientific investigation of psilocybin in the United States for approximately 25 years.

What did the Johns Hopkins 2006 study find?

The landmark 2006 study led by Roland Griffiths and colleagues at Johns Hopkins University found that a single high-dose psilocybin session in healthy volunteers reliably produced profound mystical-type experiences — characterized by unity, sacredness, deeply felt positive mood, and transcendence of time and space. More than 60% of participants rated the experience among the top five most meaningful of their lives. Follow-up assessments showed lasting increases in life satisfaction, well-being, and openness to experience.

What is a Breakthrough Therapy designation?

Breakthrough Therapy is a designation granted by the US Food and Drug Administration (FDA) to accelerate the development and review of drugs that show preliminary evidence of substantial improvement over existing therapies for serious conditions. The FDA granted this designation to psilocybin for treatment-resistant depression in 2018 and for major depressive disorder in 2019, expediting clinical trial processes and FDA review for these indications.

Where is psilocybin currently decriminalized or legal?

As of 2024, psilocybin mushrooms are decriminalized (possession not criminally prosecuted) in Denver, Oakland, Santa Cruz, Seattle, Ann Arbor, and numerous other US cities. Oregon passed Measure 109 in 2020, creating licensed psilocybin service centers under a regulated therapeutic framework. At the national level, psilocybin remains Schedule I in the US, but spores are legal for microscopy in most states (except California, Georgia, and Idaho). Countries with more permissive approaches include the Netherlands (truffles legal), Jamaica, and Brazil (mushrooms not explicitly scheduled).

What is the future of psilocybin research?

The outlook is active and evolving. Phase 3 clinical trials are underway for psilocybin-assisted therapy for major depression and treatment-resistant depression. Several biotech companies — including Compass Pathways and Usona Institute — are advancing through regulatory pipelines. Researchers at Johns Hopkins, Imperial College London, NYU, and UCSF are investigating applications in addiction, OCD, PTSD, and Alzheimer's-related anxiety. Many researchers consider FDA approval for at least one indication possible within the next five to ten years.